3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
376
Neoplasm Metastasis
21
Neoplasms
11
Advanced Breast Cancer
10
Carcinoma, Intraductal, Noninfiltrating
8
Triple Negative Breast Neoplasms
7
Osteoporosis
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Breast Diseases
7
Breast Carcinoma In Situ
6
Carcinoma, Lobular
5
Prostatic Neoplasms
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Arthralgia
4
Recurrence
3
Ovarian Neoplasms
3
Neoplasms, Hormone-Dependent
3
Squamous Cell Carcinoma of Head and Neck
2
Pain
2
Obesity
2
Neoplasms by Site
2
Multiple Endocrine Neoplasia Type 1
2
Infertility
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Neoplasms
2
Interventions
abemaciclib
2
Radiotherapy
2
sargramostim
1
ribociclib
1
palbociclib
1
niraparib
1
exemestane
1
Mastectomy, Segmental
1
Mastectomy
1
Letrozole
1
Growth and Development
1
Fulvestrant
1
Everolimus
1
Cyclophosphamide
1
Continuous Positive Airway Pressure
1
Colony-Stimulating Factors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unilateral Breast Neoplasms
×
Letrozole
×
Breast
×
Clear all
NCT06760637
2026-05-19
FourLight-3
Pfizer
Phase 3
Active not recruiting
1,035 enrolled